BlackLine
BL
24.73
+0.19
+0.77%
BlackLine
US · BL
#2936 by market cap
Listed 2016
24.73
+0.19
+0.77%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Citi Maintains BlackLine(BL.US) With Buy Rating, Cuts Target Price to $40Market Newswire · 2026/11/9
-
Rating change
William Blair Initiates BlackLine(BL.US) With Hold RatingMarket Newswire · 2026/6/4
-
Rating change
D.A. Davidson Maintains BlackLine(BL.US) With Hold RatingMarket Newswire · 2026/7/10
-
Company notice
Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Voluntarily Discloses an Announcement Regarding the Inclusion of BL-M05D1 for Injection in the Breakthrough Therapy Designation List for Patients with CLDN18.2‑Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Who Have Previously Received First-Line Standard Therapy.SZSI · 2026/9/28
-
BofA Securities Maintains BlackLine(BL.US) With Sell Rating, Maintains Target Price $26Market Newswire · 2026/11/6
-
Rating change
A Quick Look at Today's Ratings for BlackLine(BL.US), With a Forecast Between $35 to $36Market Newswire · 2026/8/5
-
Company notice
Bailitianheng: Sichuan Bailitianheng Pharmaceutical Co., Ltd. voluntarily discloses an announcement regarding the triggering of milestone payment conditions under the global strategic cooperation agreement between its wholly owned subsidiary, SystImmune, and Bristol-Myers Squibb, concerning Yizekang? (LunKang Yilong Tuodan Kang, BL-B01D1/iza-bren).SZSI · 2026/9/22
-
Rating change
BofA Securities Initiates BlackLine(BL.US) With Sell Rating, Announces Target Price $26Market Newswire · 2026/5/12
-
D.A. Davidson Downgrades BlackLine(BL.US) to Sell Rating, Announces Target Price $23Market Newswire · 2026/9/28
-
Company notice
Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Voluntarily Discloses an Announcement Regarding the Completion of Dosing in the First Subject of the Global Multicenter Phase III Clinical Trial Evaluating BL-M14D1 for Injection (DLL3 ADC) in Combination with Immunotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.SZSI · 2026/8/7
-
Company notice
Baili Tianheng: Announcement by Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on the Voluntary Disclosure of the Approval Notice for Clinical Trials of BL-M12D1 Injection (ADC) for the Treatment of Hematologic MalignanciesSZSI · 2026/9/28
-
Rating change
A Quick Look at Today's Ratings for BlackLine(BL.US), With a Forecast Between $26 to $45Market Newswire · 2026/8/6
-
Cantor Fitzgerald Maintains BlackLine(BL.US) With Hold Rating, Maintains Target Price $36Market Newswire · 2026/11/6
-
Rating change
Citi Maintains BlackLine(BL.US) With Buy Rating, Cuts Target Price to $45Market Newswire · 2026/8/6
-
Morgan Stanley Maintains BlackLine(BL.US) With Hold Rating, Cuts Target Price to $28Market Newswire · 2026/11/9
-
Company notice
Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily discloses an announcement regarding the completion of enrollment of the first subject in a Phase III clinical trial evaluating lunkangyilongtuodanmab/iza-bren (BL-B01D1/iza-bren) for the treatment of advanced HR-positive, HER2-negative breast cancer patients who have previously received endocrine therapy and experienced diSZSI · 2026/7/24
-
Rating change
A Quick Look at Today's Ratings for BlackLine(BL.US), With a Forecast Between $35 to $53Market Newswire · 2026/5/7
-
Rating change
Morgan Stanley Downgrades BlackLine(BL.US) to Hold Rating, Cuts Target Price to $33Market Newswire · 2026/7/22
-
Rating change
Citi Maintains BlackLine(BL.US) With Buy Rating, Maintains Target Price $53Market Newswire · 2026/6/25
-
Rating change
Citi Maintains BlackLine(BL.US) With Buy Rating, Cuts Target Price to $53Market Newswire · 2026/5/8
-
Rating change
Analysts Offer Insights on Technology Companies: Klaviyo, Inc. Class A (KVYO), BlackLine (BL) and Infineon Technologies AG (OtherIFNNF)TipRanks · 2026/5/6
-
Rating change
BofA Securities Maintains BlackLine(BL.US) With Sell Rating, Maintains Target Price $26Market Newswire · 2026/7/23
-
Baili Tianheng (688506.SH): BL-M05D1 for Injection (Claudin18.2 ADC) for patients with CLDN18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma who have previously received first-line standard therapy has been included in the list of breakthrough therapy designations.Gelonghui Finance · 2026/9/27
-
Rating change
A Quick Look at Today's Ratings for BlackLine(BL.US), With a Forecast Between $37 to $50Market Newswire · 2026/5/6
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.
BlackLine discussion 0 comments